News25/Ratings0
Latest news
25 items- PRUrovant Sciences Announces Positive Topline Results of Phase 2a Trial of its Potential Novel Gene Therapy, URO-902Study showed clinically meaningful impact on common symptoms of overactive bladder (OAB) compared to placebo from baseline to week 12 Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced positive topline results from its Phase 2a, double-blind, placebo-controlled exploratory study of URO-902, an investigational, novel, locally injected gene therapy product (plasmid human cDNA encoding maxi-K channel), in patients with overactive bladder (OAB), who were not well managed by oral therapies. "URO-902 showed a clinically meaningful and statistically significant effect on a number of relevant outcome measures in OAB including number of micturitions, urgency
- PRUrovant Sciences Announces Publication in Advances in Therapy of Analyses of Patient-Perceived Meaningfulness of Improvement in Symptom Reduction for Overactive Bladder Patients Treated with GEMTESA® (vibegron) 75 mgData from the 12-week EMPOWUR trial regarding patient perceptions of improvement of OAB symptoms show that significantly more patients treated once-daily with GEMTESA® (vibegron) experienced patient-perceived improvements due to the reduction in micturition frequency (urination), urinary urgency episodes, and urge urinary incontinence episodes vs. placebo. This analysis supports that the statistically significant reductions in clinical endpoints seen in the EMPOWUR trial are meaningful to patients. Urovant Sciences, Inc., a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced today that the journal Advances in Therapy has published patient-perception data supporting clinica
- PRUrovant Sciences Announces Publication in Blood Pressure Monitoring of Positive Ambulatory Blood Pressure Study Results for GEMTESA® (vibegron) 75 mg in Overactive Bladder PatientsData from a dedicated ambulatory blood pressure study showed once-daily treatment with GEMTESA® was not associated with statistically significant or clinically meaningful effects on blood pressure or heart rate Urovant Sciences, Inc., a wholly- owned subsidiary of Sumitovant Biopharma Ltd., announced today that the journal Blood Pressure Monitoring has published the ambulatory blood pressure data on its recently-approved overactive bladder (OAB) therapy, GEMTESA® (vibegron) in the U.S. The peer-reviewed publication is currently available online and the print article is scheduled to be published in an upcoming issue of the journal. In a dedicated, double-blind, placebo-controlled ambulat
- SECSEC Form 15-12B filed by Urovant Sciences Ltd.15-12B - Urovant Sciences Ltd. (0001740547) (Filer)
- SECSEC Form EFFECT filed by Urovant Sciences Ltd.EFFECT - Urovant Sciences Ltd. (0001740547) (Filer)
- INSIDERSEC Form 4: E. Bryan Smith disposed to the issuer $0 worth of Common Shares (124,447 units at $0.00), decreasing direct ownership by 100% to 0 units4 - Urovant Sciences Ltd. (0001740547) (Issuer)
- INSIDERSEC Form 4: Sef Kurstjens disposed to the issuer $0 worth of Common Shares (21,480 units at $0.00), decreasing direct ownership by 100% to 0 units4 - Urovant Sciences Ltd. (0001740547) (Issuer)
- INSIDERSEC Form 4: M. James Hindman disposed to the issuer $0 worth of Common Shares (9,000 units at $0.00), decreasing direct ownership by 100% to 0 units4 - Urovant Sciences Ltd. (0001740547) (Issuer)
- INSIDERSEC Form 4: Cornelia Haag-Molkenteller disposed to the issuer $0 worth of Common Shares (141,348 units at $0.00), decreasing direct ownership by 100% to 0 units4 - Urovant Sciences Ltd. (0001740547) (Issuer)
- INSIDERSEC Form 4: Ajay Bansal disposed to the issuer $0 worth of Common Shares (140,098 units at $0.00), decreasing direct ownership by 100% to 0 units4 - Urovant Sciences Ltd. (0001740547) (Issuer)
- INSIDERSEC Form 4: Pierre Legault disposed to the issuer $0 worth of Common Shares (21,480 units at $0.00), decreasing direct ownership by 100% to 0 units4 - Urovant Sciences Ltd. (0001740547) (Issuer)
- INSIDERSEC Form 4: Jr. A. James Robinson disposed to the issuer $0 worth of Common Shares (8,385 units at $0.00), decreasing direct ownership by 100% to 0 units4 - Urovant Sciences Ltd. (0001740547) (Issuer)
- INSIDERSEC Form 4: Walt Johnston disposed to the issuer $0 worth of Common Shares (109,139 units at $0.00), decreasing direct ownership by 100% to 0 units4 - Urovant Sciences Ltd. (0001740547) (Issuer)
- INSIDERSEC Form 4: S Myrtle Potter disposed to the issuer $0 worth of Common Shares (21,480 units at $0.00), decreasing direct ownership by 100% to 0 units4 - Urovant Sciences Ltd. (0001740547) (Issuer)
- INSIDERSEC Form 4: Christine Ocampo disposed to the issuer $0 worth of Common Shares (78,781 units at $0.00), decreasing direct ownership by 100% to 0 units4 - Urovant Sciences Ltd. (0001740547) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Urovant Sciences Ltd.SC 13D/A - Urovant Sciences Ltd. (0001740547) (Subject)
- SECSEC Form SC 13E3/A filed by Urovant Sciences Ltd.SC 13E3/A - Urovant Sciences Ltd. (0001740547) (Subject)
- SECSEC Form S-8 POS filed by Urovant Sciences Ltd.S-8 POS - Urovant Sciences Ltd. (0001740547) (Filer)
- SECSEC Form S-8 POS filed by Urovant Sciences Ltd.S-8 POS - Urovant Sciences Ltd. (0001740547) (Filer)
- SECSEC Form S-8 POS filed by Urovant Sciences Ltd.S-8 POS - Urovant Sciences Ltd. (0001740547) (Filer)
- SECSEC Form POS AM filed by Urovant Sciences Ltd.POS AM - Urovant Sciences Ltd. (0001740547) (Filer)
- SECSEC Form 25-NSE filed by Urovant Sciences Ltd.25-NSE - Urovant Sciences Ltd. (0001740547) (Subject)
- SECUrovant Sciences Ltd. filed SEC Form 8-K: Completion Of Acquisition Or Dispositive Of Assets, Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Material Modification To Rights Of Security Holders, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Amendments To Articles Of Incorporation Or Bylaws, Other Events, Financial Statements And Exhibits8-K - Urovant Sciences Ltd. (0001740547) (Filer)
- PRSumitovant Biopharma Completes Acquisition of Urovant Sciences Sumitovant BiopharmaNEW YORK, LONDON, IRVINE, CA & BASEL, SWITZERLAND, March 29, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma and Urovant Sciences (formerly Nasdaq: UROV) jointly announced today the completion of the merger in which Sumitovant has acquired all outstanding shares of Urovant Sciences. The merger agreement and the merger were approved on March 23, 2021 by the affirmative vote of holders of a majority of Urovant’s outstanding shares, and by holders of a majority of Urovant's outstanding shares that are not held by Sumitovant. “As with other companies in the Sumitovant family, Urovant will be privately held and maintain its distinct culture and focus while benefiting from the strateg
- SECSEC Form 8-K filed by Urovant Sciences Ltd.8-K - Urovant Sciences Ltd. (0001740547) (Filer)
UROV FAQ
5 questionsWhere does UROV stock trade?
Urovant Sciences Ltd. (UROV) is listed on NASDAQ.What sector and industry is UROV in?
Urovant Sciences Ltd. operates in the Health Care sector, Major Pharmaceuticals industry.When did Urovant Sciences Ltd. go public?
Urovant Sciences Ltd. (UROV) completed its IPO in 2018.What companies are similar to UROV?
Notable peers in the same industry include DRNA (Dicerna Pharmaceuticals, Inc.), TRIL (Trillium Therapeutics Inc.), KDMN (Kadmon Holdings, Inc.), FLXN (Flexion Therapeutics, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.). Compare UROV side-by-side with any of them on Quantisnow.How can I track UROV on Quantisnow?
Quantisnow aggregates Urovant Sciences Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow UROV to receive live email and push alerts on every new disclosure.